Cost Effectiveness of Teriparatide for Postmenopausal Osteoporosis: A Systematic Review.
Mohammad Alimoradnori, Ali Abutorabi, Mozhdeh Zabihiyeganeh et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the cost effectiveness of teriparatide for postmenopausal osteoporosis, analyzing 22 economic evaluations. The majority indicated that teriparatide is not cost effective under typical conditions, with exceptions in scenarios involving lower drug prices or specific assumptions. Variability in cost-effectiveness ratios was noted across different regions.
Key findings
- Most studies concluded teriparatide is not cost effective under general conditions.
- Cost effectiveness improved in scenarios with reduced drug prices or generic alternatives.
- Variability in willingness-to-pay thresholds significantly affected cost-effectiveness outcomes.
- Few studies considered indirect costs, highlighting a gap in economic evaluations.
Why it matters
Understanding the cost effectiveness of teriparatide is crucial for healthcare decision-makers, as it informs resource allocation and treatment guidelines for managing postmenopausal osteoporosis, a condition with significant economic implications.
What to keep in mind
Heterogeneity among studies, potential language bias from including only English publications, and methodological variations limited comparability.